We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current 0HD2 market cap is 13B. The company's latest EPS is USD -2.1566 and P/E is -113.08.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 492.85M | 844.29M | 1.04B | 1.83B | 2.25B |
| Operating Income | -828.44M | -708.65M | -785.07M | -282.18M | -176.89M |
| Net Income | -858.28M | -852.82M | -1.13B | -440.24M | -278.16M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 3.41B | 3.64B | 3.55B | 3.83B | 4.24B |
| Total Liabilities | 2.39B | 3.06B | 3.7B | 4.05B | 4.17B |
| Total Equity | 1.02B | 588.2M | -158.22M | -220.64M | 67.09M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -614.96M | -641.69M | -541.27M | 104.16M | -8.31M |
| Investing | -435.52M | -273.3M | 169.35M | -336.35M | -116.84M |
| Financing | 994.98M | 1.25B | 425.75M | 172.13M | 294.16M |
| Market Cap | 13B |
| Price to Earnings Ratio | -113.08 |
| Price to Sales Ratio | 13.99 |
| Price to Cash Ratio | 32.55 |
| Price to Book Ratio | 468.84 |
| Dividend Yield | - |
| Shares Outstanding | 128.98M |
| Average Volume (1 week) | 82 |
| Average Volume (1 Month) | 288 |
| 52 Week Change | 0.00% |
| 52 Week High | 100.80 |
| 52 Week Low | 100.80 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Alnylam Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.alnylam.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
